Learn more about whether Gilead Sciences, Inc. or Insmed Incorporated is a better investment based on AAII's A+ Investor ...

Gilead Sciences, Inc., a biopharmaceutical company ... an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious ...

Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the fourth quarter and full year 2024.

Wall Street analysts expect Gilead Sciences (GILD ... According to the collective judgment of analysts, 'Product Sales- AmBisome- U.S.' should come in at $7.44 million. The estimate indicates ...

16 analysts have shared their evaluations of Gilead Sciences GILD during the recent three months, expressing a mix of bullish and bearish perspectives. The table below offers a condensed view of ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly effective medicine. However, Ben Hargreaves finds that the company’s ...

Gilead Sciences has shored up its antibody-drug conjugate pipeline by licensing a candidate from German biotech Tubulis in a deal worth up to $415 million. The agreement includes an upfront ...

Looking at the universe of stocks we cover at Dividend Channel, in trading on Friday, shares of Gilead Sciences Inc (Symbol: GILD) were yielding above the 3% mark based on its quarterly dividend ...